PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study-Reference-Cited by-同舟云学术

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

Published:2019-11-19 Issue:1 Volume:80 Page:99-108
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Petrylak Daniel P.¹,Vogelzang Nicholas J.²,Chatta Kamal³,Fleming Mark T.⁴,Smith David C.⁵,Appleman Leonard J.⁶,Hussain Arif⁷,Modiano Manuel⁸,Singh Parminder⁹,Tagawa Scott T.¹⁰,Gore Ira¹¹,McClay Edward F.¹²,Mega Anthony E.¹³,Sartor A. Oliver¹⁴^ORCID,Somer Bradley¹⁵,Wadlow Raymond¹⁶,Shore Neal D.¹⁷,Olson William C.¹⁸,Stambler Nancy¹⁸,DiPippo Vincent A.¹⁸^ORCID,Israel Robert J.¹⁸

Affiliation:

1. Department of UrologyYale University New Haven Connecticut

2. Comprehensive Cancer Centers of Nevada Las Vegas Nevada

3. Virginia Mason Medical Center Seattle Washington

4. Virginia Oncology Associates Norfolk Virginia

5. University of Michigan Ann Arbor Michigan

6. Hillman Cancer CenterUniversity of Pittsburgh Pittsburgh Pennsylvania

7. University of Maryland Baltimore Maryland

8. Arizona Clinical Research Center Tucson Arizona

9. Mayo Clinic Phoenix Arizona

10. Weill Cornell Medical College New York New York

11. Alabama Oncology Birmingham Alabama

12. California Cancer Associates for Research and Excellence Encinitas California

13. The Miriam Hospital Providence Rhode Island

14. School of MedicineTulane University New Orleans Louisiana

15. West Cancer Center and Research Institute Memphis Tennessee

16. Virginia Cancer Specialists Fairfax Virginia

17. Carolina Urologic Research Center Myrtle Beach South Carolina

18. Progenics Pharmaceuticals, Inc New York New York

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23922

Reference37 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. The Epidemiology of Prostate Cancer

3. Cancer statistics, 2019

4. Metastatic castration‐resistant prostate cancer previously treated with docetaxel‐based chemotherapy: treatment patterns from the PROXIMA prospective registry;Akaza H;J Glob Oncol,2018

5. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future;Bioorganic Chemistry;2024-12

2. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies;Cancers;2024-09-06

3. Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate;World Journal of Urology;2024-07-11

4. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

5. Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer;Diseases;2024-05-02